The Economic Impact of Introducing RefluxStop for Refractory Gastroesophageal Reflux Disease on the Italian Healthcare System.
Journal
PharmacoEconomics - open
ISSN: 2509-4254
Titre abrégé: Pharmacoecon Open
Pays: Switzerland
ID NLM: 101700780
Informations de publication
Date de publication:
27 Aug 2024
27 Aug 2024
Historique:
accepted:
12
08
2024
medline:
27
8
2024
pubmed:
27
8
2024
entrez:
27
8
2024
Statut:
aheadofprint
Résumé
Gastroesophageal reflux disease (GERD) is a common ailment associated with troublesome symptoms. The standard of care in Italy involves initial treatment with proton pump inhibitor (PPI)-based medical management or laparoscopic Nissen fundoplication (LNF) for patients unwilling to continue or intolerant of long-term PPI therapy. RefluxStop is a novel medical device, intended for laparoscopic implantation, that has recently proven to be an efficacious and cost-effective treatment option for patients with GERD. This analysis aims to describe the short-term budget impact of introducing RefluxStop as a GERD treatment option within the Italian National Health Service (SSN). A model adherent to international best practice recommendations was developed to estimate the budget impact of introducing RefluxStop over a 5-year time horizon. Two scenarios were considered: one without RefluxStop (i.e., comprising PPI therapy, LNF, and magnetic sphincter augmentation using the LINX system); and one with RefluxStop (i.e., addition of RefluxStop to the three treatment options previously mentioned). Clinical benefits and costs associated with each intervention were included in the analysis. Over 5 years, the introduction of RefluxStop resulted in avoidance of 95 surgical failures, 11 reoperations, and 64 endoscopic esophageal dilations. Introduction of RefluxStop resulted in an almost neutral impact on the existing budget with a 0.316% increase in the annual Italian SSN spending on GERD treatment. Introduction of RefluxStop as a GERD treatment option in Italy is likely to be associated with substantial clinical benefits and a marginal budget impact.
Identifiants
pubmed: 39190268
doi: 10.1007/s41669-024-00521-7
pii: 10.1007/s41669-024-00521-7
doi:
Types de publication
Journal Article
Langues
eng
Informations de copyright
© 2024. The Author(s).
Références
Martinucci I, Natilli M, Lorenzoni V, Pappalardo L, Monreale A, Turchetti G, et al. Gastroesophageal reflux symptoms among Italian university students: epidemiology and dietary correlates using automatically recorded transactions. BMC Gastroenterol. 2018;18(1):116.
doi: 10.1186/s12876-018-0832-9
pubmed: 30016938
pmcid: 6050672
Pacini F, Calabrese C, Cipolletta L, Valva MD, Russo A, Savarino V, et al. Burden of illness in Italian patients with gastro-oesophageal reflux disease. Curr Med Res Opin. 2005;21(4):495–502.
doi: 10.1185/030079905X38231
pubmed: 15899097
GBD 2017 Gastro-oesophageal Reflux Disease Collaborators. The global, regional, and national burden of gastro-oesophageal reflux disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5(6):561-81.
Ayazi S, Hagen JA, Chan LS, DeMeester SR, Lin MW, Ayazi A, et al. Obesity and gastroesophageal reflux: quantifying the association between body mass index, esophageal acid exposure, and lower esophageal sphincter status in a large series of patients with reflux symptoms. J Gastrointest Surg. 2009;13(8):1440–7.
doi: 10.1007/s11605-009-0930-7
pubmed: 19475461
pmcid: 2710497
Bredenoord AJ, Pandolfino JE, Smout AJ. Gastro-oesophageal reflux disease. Lancet. 2013;381(9881):1933–42.
doi: 10.1016/S0140-6736(12)62171-0
pubmed: 23477993
El-Serag HB. Time trends of gastroesophageal reflux disease: a systematic review. Clin Gastroenterol Hepatol. 2007;5(1):17–26.
doi: 10.1016/j.cgh.2006.09.016
pubmed: 17142109
El-Serag HB, Sweet S, Winchester CC, Dent J. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2014;63(6):871–80.
doi: 10.1136/gutjnl-2012-304269
pubmed: 23853213
Lagergren J. Influence of obesity on the risk of esophageal disorders. Nat Rev Gastroenterol Hepatol. 2011;8(6):340–7.
doi: 10.1038/nrgastro.2011.73
pubmed: 21643038
Ness-Jensen E, Lindam A, Lagergren J, Hveem K. Changes in prevalence, incidence and spontaneous loss of gastro-oesophageal reflux symptoms: a prospective population-based cohort study, the HUNT study. Gut. 2012;61(10):1390–7.
doi: 10.1136/gutjnl-2011-300715
pubmed: 22190483
Bert F, Pompili E, Lo Moro G, Corradi A, Sagrawa Caro A, Gualano MR, et al. Prevalence of gastro-oesophageal reflux symptoms: an Italian cross-sectional survey focusing on knowledge and attitudes towards lifestyle and nutrition. Int J Clin Pract. 2021;75(3): e13758.
doi: 10.1111/ijcp.13758
pubmed: 33098613
Darbà J, Kaskens L, Plans P, Elizalde JI, Coma M, Cuomo R, et al. Epidemiology and societal costs of gastroesophageal reflux disease and Barrett’s syndrome in Germany, Italy and Spain. Expert Rev Pharmacoecon Outcomes Res. 2011;11(2):225–32.
doi: 10.1586/erp.11.5
pubmed: 21476824
King A, MacDonald C, Orn C. Understanding gastro-oesophageal reflux disease: a patient-cluster analysis. Int J Clin Pract. 2008;62(12):1838–43.
doi: 10.1111/j.1742-1241.2008.01929.x
pubmed: 19166432
National Institute for Health and Care Excellence. Clinical guideline [CG184]: Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management. London: National Institute for Health and Care Excellence (NICE); 2019.
Bjelović M, Harsányi L, Altorjay Á, Kincses Z, Forsell P. Non-active implantable device treating acid reflux with a new dynamic treatment approach: 1-year results : RefluxStop™ device; a new method in acid reflux surgery obtaining CE mark. BMC Surg. 2020;20(1):159.
doi: 10.1186/s12893-020-00794-9
pubmed: 32689979
pmcid: 7370422
Implantica. Implantica receives CE Mark Approval for RefluxStop, a potential Paradigm shift in the Treatment for Acid reflux. [Available from: https://www.implantica.com/media/press-releases/2018/implantica-receives-ce-mark-approval-for-refluxstop-a-potential-paradigm-shift-in-the-treatment-for-acid-reflux/ .
Harper S, Grodzicki L, Mealing S, Gemmill L, Goldsmith PJ, Ahmed AR. Cost-effectiveness of a novel, non-active implantable device as a treatment for refractory gastro-esophageal reflux disease. J Med Econ. 2023;26(1):603–13.
doi: 10.1080/13696998.2023.2201063
pubmed: 37042668
Sullivan SD, Mauskopf JA, Augustovski F, Jaime Caro J, Lee KM, Minchin M, et al. Budget impact analysis-principles of good practice: report of the ISPOR 2012 budget impact analysis good practice II task force. Value Health. 2014;17(1):5–14.
doi: 10.1016/j.jval.2013.08.2291
pubmed: 24438712
Brosa M, Gisbert R, Rodríguez Barrios J, Soto J. Principios, métodos y aplicaciones del análisis del impacto presupuestario en sanidad. Span Res Articles. 2005;2:65–79.
Mauskopf JA, Sullivan SD, Annemans L, Caro J, Mullins CD, Nuijten M, et al. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices–budget impact analysis. Value Health. 2007;10(5):336–47.
doi: 10.1111/j.1524-4733.2007.00187.x
pubmed: 17888098
Istat Statistics [Available from: http://dati.istat.it/ .
Zagari RM, Fuccio L, Wallander MA, Johansson S, Fiocca R, Casanova S, et al. Gastro-oesophageal reflux symptoms, oesophagitis and Barrett’s oesophagus in the general population: the Loiano-Monghidoro study. Gut. 2008;57(10):1354–9.
doi: 10.1136/gut.2007.145177
pubmed: 18424568
Dent J, El-Serag HB, Wallander MA, Johansson S. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2005;54(5):710–7.
doi: 10.1136/gut.2004.051821
pubmed: 15831922
pmcid: 1774487
NHS Dorset Clinical Commissioning Group. In Focus: High-Cost PPIs [Available from: https://www.dorsetccg.nhs.uk/Downloads/aboutus/medicines-management/Other%20Guidelines/Gastroenterology%20High%20cost%20PPI%20in%20focus%200519%20%282%29.pdf?UNLID=97481392021984165 .
Weickum J, Higgins A, Wright G, Qadeer R, Ferko N. PGI11 A budget impact model for medication refractory gastroesophageal reflux disease pateints treated with laparoscopic nissen fundoplication or magnetic sphincter augmentation: an Italian payer perspective. Value Health. 2019;22:S618.
doi: 10.1016/j.jval.2019.09.1134
Shemilt I, Thomas J, Morciano M. A web-based tool for adjusting costs to a specific target currency and price year. Evid Policy. 2010;6:51–60.
doi: 10.1332/174426410X482999
Nochaiwong S, Ruengorn C, Awiphan R, Koyratkoson K, Chaisai C, Noppakun K, et al. The association between proton pump inhibitor use and the risk of adverse kidney outcomes: a systematic review and meta-analysis. Nephrol Dial Transplant. 2018;33(2):331–42.
doi: 10.1093/ndt/gfw470
pubmed: 28339835
Batchelor R, Kumar R, Gilmartin-Thomas JFM, Hopper I, Kemp W, Liew D. Systematic review with meta-analysis: risk of adverse cardiovascular events with proton pump inhibitors independent of clopidogrel. Aliment Pharmacol Ther. 2018;48(8):780–96.
doi: 10.1111/apt.14955
pubmed: 30178881
Nassar Y, Richter S. Proton-pump inhibitor use and fracture risk: an updated systematic review and meta-analysis. J Bone Metab. 2018;25(3):141–51.
doi: 10.11005/jbm.2018.25.3.141
pubmed: 30237993
pmcid: 6135649
Nguyen PA, Islam M, Galvin CJ, Chang CC, An SY, Yang HC, et al. Meta-analysis of proton pump inhibitors induced risk of community-acquired pneumonia. Int J Qual Health Care. 2020;32(5):292–9.
doi: 10.1093/intqhc/mzaa041
pubmed: 32436582
Trifan A, Stanciu C, Girleanu I, Stoica OC, Singeap AM, Maxim R, et al. Proton pump inhibitors therapy and risk of Clostridium difficile infection: systematic review and meta-analysis. World J Gastroenterol. 2017;23(35):6500–15.
doi: 10.3748/wjg.v23.i35.6500
pubmed: 29085200
pmcid: 5643276
Poly TN, Lin MC, Syed-Abdul S, Huang CW, Yang HC, Li YJ. Proton pump inhibitor use and risk of gastric cancer: current evidence from epidemiological studies and critical appraisal. Cancers (Basel). 2022;14(13):5.
doi: 10.3390/cancers14133052
Bonavina L, Fisichella PM, Gavini S, Lee YY, Tatum RP. Clinical course of gastroesophageal reflux disease and impact of treatment in symptomatic young patients. Ann N Y Acad Sci. 2020;1481(1):117–26.
doi: 10.1111/nyas.14350
pubmed: 32266986
Yamasaki T, Hemond C, Eisa M, Ganocy S, Fass R. The changing epidemiology of gastroesophageal reflux disease: are patients getting younger? J Neurogastroenterol Motil. 2018;24(4):559–69.
doi: 10.5056/jnm18140
pubmed: 30347935
pmcid: 6175565
Scarpignato C, Gatta L, Zullo A, Blandizzi C. Effective and safe proton pump inhibitor therapy in acid-related diseases—A position paper addressing benefits and potential harms of acid suppression. BMC Med. 2016;14(1):179.
doi: 10.1186/s12916-016-0718-z
pubmed: 27825371
pmcid: 5101793
Rettura F, Bronzini F, Campigotto M, Lambiase C, Pancetti A, Berti G, et al. Refractory gastroesophageal reflux disease: a management update. Front Med (Lausanne). 2021;8: 765061.
doi: 10.3389/fmed.2021.765061
pubmed: 34790683
pmcid: 8591082
Garg SK, Gurusamy KS. Laparoscopic fundoplication surgery versus medical management for gastro-oesophageal reflux disease (GORD) in adults. Cochrane Database Syst Rev. 2015;2015(11):3243.
Lundell L, Bell M, Ruth M. Systematic review: laparoscopic fundoplication for gastroesophageal reflux disease in partial responders to proton pump inhibitors. World J Gastroenterol. 2014;20(3):804–13.
doi: 10.3748/wjg.v20.i3.804
pubmed: 24574753
pmcid: 3921489
d’Errico M, Pavlova M, Spandonaro F. The economic burden of obesity in Italy: a cost-of-illness study. Eur J Health Econ. 2022;23(2):177–92.
doi: 10.1007/s10198-021-01358-1
pubmed: 34347176
Tack J, Becher A, Mulligan C, Johnson DA. Systematic review: the burden of disruptive gastro-oesophageal reflux disease on health-related quality of life. Aliment Pharmacol Ther. 2012;35(11):1257–66.
doi: 10.1111/j.1365-2036.2012.05086.x
pubmed: 22486579